TuHURA Biosciences, Inc./NV financial data

Symbol
HURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10500 University Center Dr., Suite 110, Tampa, FL
State of incorporation
NV
Fiscal year end
December 31
Former names
Kintara Therapeutics, Inc. (to 10/22/2024), DelMar Pharmaceuticals, Inc. (to 8/18/2020), Berry Only Inc. (to 1/18/2013)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 316 % +185%
Debt-to-equity 45.4 % -97.3%
Return On Equity -179 % +0.66%
Return On Assets -146 % -1.44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.7M shares
Common Stock, Shares, Outstanding 42.3M shares +248%
Entity Public Float 14.9M USD
Common Stock, Value, Issued 42.3K USD +248%
Weighted Average Number of Shares Outstanding, Basic 1.59M shares +3137%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 252K USD -86.4%
General and Administrative Expense 1.96M USD +77.4%
Nonoperating Income (Expense) 179K USD +84.5%
Net Income (Loss) Attributable to Parent -2.16M USD +27%
Earnings Per Share, Basic -1.37 USD/shares +97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.7M USD +245%
Other Assets, Current 959K USD +94.2%
Assets, Current 19.6M USD +372%
Property, Plant and Equipment, Net 123K USD -32.3%
Operating Lease, Right-of-Use Asset 199K USD +857%
Other Assets, Noncurrent 33.8K USD
Assets 20M USD +358%
Accounts Payable, Current 3.15M USD +68.9%
Accrued Liabilities, Current 1.16M USD -17.9%
Liabilities, Current 5.33M USD +48.2%
Operating Lease, Liability, Noncurrent 42.7K USD
Liabilities 5.37M USD -9.25%
Accumulated Other Comprehensive Income (Loss), Net of Tax 21K USD 0%
Retained Earnings (Accumulated Deficit) -111M USD -25.6%
Stockholders' Equity Attributable to Parent 14.6M USD
Liabilities and Equity 20M USD +358%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.89M USD -43.4%
Net Cash Provided by (Used in) Financing Activities -2M USD -205%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 42.3M shares +248%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.89M USD -43.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.7M USD +245%
Deferred Tax Assets, Valuation Allowance 46.5M USD +118%
Deferred Tax Assets, Gross 46.5M USD +118%
Depreciation 17K USD +13.3%
Property, Plant and Equipment, Gross 2.21M USD +2.69%
Operating Lease, Liability, Current 160K USD +668%
Lessee, Operating Lease, Liability, to be Paid, Year Two 43.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 173K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +125%
Preferred Stock, Shares Authorized 5M shares 0%
Deferred Tax Assets, Net of Valuation Allowance 51.2K USD -21.8%
Share-based Payment Arrangement, Expense 98K USD -38.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%